Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

NCT ID: NCT06181370

Last Updated: 2025-12-31

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 145 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-01
• Study Completion Date: 2026-06-30

Brief Summary

The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C).

Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of AGMB-447 administered via nebulizer in Part A, B and C, respectively.

Conditions

IPF

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AGMB-447

Participants will receive a single dose of AGMB-447 (part A), multiple doses of AGMB-447 over 7 days (part B) or multiple doses of AGMB-447 over 14 days (part C)

Group Type: EXPERIMENTAL

AGMB-447

Intervention Type: DRUG

AGMB-447 inhaled drug

placebo

Participants will receive a single dose of placebo (part A), multiple doses of placebo over 7 days (part B) or multiple doses of placebo over 14 days (part C)

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: OTHER

placebo inhaled drug

Interventions

AGMB-447

AGMB-447 inhaled drug

Intervention Type: DRUG

placebo

placebo inhaled drug

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male and female participants aged between 18-55 years inclusive, at the time of informed consent.
• Participants must have FEV1 ≥80% predicted at screening and prior to randomization on Day -1 or Day 1 of treatment period 1 (using Global Lung Index, GLI 2012, predicted values).
• Participant must have a body weight of at least 50.0 kg and BMI ≥ 18 and ≤ 32 kg/m2 at screening.
• Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG, spirometry and clinical laboratory assessments at the time of screening, as judged by the Investigator.

• Male and female participants aged >40 years inclusive, at the time of informed consent.
• Participants must have a confirmed diagnosis of IPF (IPF based on 2022 ATS/ERS/JRS/ALAT Guidelines) as confirmed by the Investigator based on chest High Resolution Computed Tomography Scan taken within 5 years of screening and, only if available, surgical lung biopsy)
• Participants must be either:
• Receiving a stable, well tolerated dose of Nintedanib for 3 months prior to screening for the treatment of IPF
• OR
• Receiving no current antifibrotic medication for the treatment of IPF. This includes those who have never received treatment and those who have stopped medication due to intolerance for any reason, except non-responsiveness, for at least 6 weeks prior to screening.
• Participants must have FVC ≥40% of predicted (using Global Lung Index, GLI 2012, predicted values) at screening.
• Participants must have DLCO (corrected for hemoglobin ) ≥ 25% of predicted (using Global Lung Index, GLI 2017, predicted values) at screening.
• Participants must have FEV1 ≥30% predicted at screening and prior to randomization on Day -1 or Day 1 (using Global Lung Index, GLI 2012, predicted values).

Exclusion Criteria

• History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical study or expose the participant to undue risk as judged by the Investigator.
• After a minimum of 10 minutes supine rest at the time of screening or prior to randomization on Day -1 or Day 1 of treatment period 1:

• Systolic blood pressure <90 or >150 mmHg, or
• Diastolic blood pressure <50 or >95 mmHg, or
• Pulse <40 or >90 bpm
• Any clinically significant abnormalities in resting ECG at the time of screening or prior to randomization on Day -1 or Day 1 of treatment period 1 including prolonged QTcF (>450 ms for males; >470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator.
• Clinically significant abnormalities in renal function at screening including any of the following:

• Serum creatinine >2 x ULN
• eGFR <80 mL/min
• Clinically significant abnormalities in liver function at screening including any of the following:

• Bilirubin >1.5 x ULN
• Aminotransferases >2 x ULN
• ALP >1.5 x ULN

• History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical study or expose the participant to undue risk as judged by the Investigator.
• History or presence of any clinically significant pulmonary abnormalities, with the exception of IPF, in the opinion of the Investigator.
• Relevant airways obstruction (pre-bronchodilator FEV1/ FVC < 0.7) at screening.
• Any clinically significant abnormalities in resting ECG at the time of screening or prior to randomization on Day -1 or Day 1 including prolonged QTcF (>450 ms for males; >470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator.
• Clinically significant abnormalities in liver function at screening including any of the following:

• Bilirubin >1.5 x ULN
• Aminotransferases >2 x ULN
• ALP >1.5 x ULN
• Acute IPF exacerbation within 3 months prior to screening and/or during the screening period prior to dose on Day 1 as determined by the Investigator.
• Any signs of respiratory tract infection within 4 weeks of screening or prior to dosing on Day 1 that is deemed clinically significant in the opinion of the Investigator.
• Malignancy within the past 5 years of screening with the exception of in situ removal of basal cell carcinoma or resected benign colonic polyps.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Agomab Spain S.L.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philippe Wiesel, MD

Role: STUDY_DIRECTOR

Agomab Therapeutics

Locations

Medicines Evaluation Unit Ltd. an IQVIA business

Manchester, , United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Tim Van Kaem

Role: CONTACT

Phone: 0032 3318 91 70

Email: clinicalstudies@agomab.com

Other Identifiers

AGMB-447-C101

Identifier Type: -

Identifier Source: org_study_id